Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and fees upon reaching certain regulatory milestones. In addition, MC2 will be entitled to receive fees for sales milestones and double-digit royalties on net sales.
Pharmaceutical and consumer healthcare group Hyphens Pharma International (SGX:1J5
) has announced that its subsidiary Hyphens Pharma has entered into an agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora Cream in the Asean region.
The exclusive licence, supply and commercialisation agreement for Wynzora, a leading topical treatment for plaque psoriasis, extends to all future product extensions and improvements of the product.
